HANSHOW
13.6.2024 11:51:29 CEST | Business Wire | Press release
Hanshow, a global leader in Electronic Shelf Labels (ESL) and digital retail solutions, proudly participated in the first NRF Big Show 2024 Asia Pacific, held in Singapore from June 11-13. Organized by the National Retail Federation (NRF), this highly anticipated event marked a significant milestone in the retail industry, bringing together the best and brightest minds from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612653287/en/
Hanshow at NRF APAC 2024 (Photo: Business Wire)
A Leap Forward in Shopper Experience and Store Operation
At this prestigious event, Hanshow introduced its Smart Cart Solution, developed with Microsoft on the Azure Open AI platform, leveraging Generative AI (GenAI) to enhance customer experience and store operations in a smarter, more connected retail ecosystem. This solution featured an AI copilot for personalized shopping, offering tailored recommendations and syncing online and in-store customer profiles for a seamless shopping experience.
Additionally, the Smart Cart enables skip-the-line checkout for faster, more convenient transactions. Retailers benefited from retail media revenue by displaying location-based advertisements and offering smart product recommendations, boosting their revenue. The solution also provided valuable data on shopper behavior and product performance.
In addition, Hanshow’s Lumina digital display series revolutionizes in-store marketing by integrating with GenAI, providing a state-of-the-art digital marketing solution. With the power of GPT-4 and DALL-E3, users can effortlessly craft product POP posters, atmospheric marketing visuals, and persuasive product copy through simple text commands.
"Our co-innovated solutions with Microsoft, showcased at this NRF, mark a significant step in revolutionizing the retail experience," said Shiguo Hou, CEO of Hanshow. "Together, we are not only redefining shopping but also empowering retailers with the tools to excel in a competitive landscape and forge a shared vision for the future. We’re honored to have jointly held our Retail Conference with Microsoft in Singapore, and our meeting with Microsoft APAC CEO Ahmed Mazhari discussed yielded new areas for possible future cooperation."
Sustainability and Growth Vision
Hanshow's vision for a greener future in retail outlines the steps businesses must take to balance decarbonization and sustainability with creating value for customers, employees, and stakeholders. A key component of this vision is the electronic shelf label (ESL) solution, which transforms retail operations by enabling dynamic pricing, real-time promotions, and efficient inventory management. ESLs help retailers significantly reduce their carbon footprint by minimizing food waste and enhancing resource efficiency.
Additionally, Hanshow has expanded its offerings with a digital energy solution. Key aspects of this solution include globally integrated local teams, R&D innovation, 24/7 butler service, a one-stop turnkey PV digital energy system, and flexible financing options with PPA resources. These initiatives drive sustainability and business growth by providing tailored PV, charging, and digital energy management systems.
Hanshow’s participation in NRF APAC underscored its commitment to driving innovation in the retail sector and supporting the digital transformation of retailers worldwide. The hands-on experience provided to attendees was a glimpse into a future where our technology is the cornerstone of a more intelligent, efficient, and eco-friendly retail landscape. As we move forward, Hanshow is committed to continuing to lead and support the global retail community in embracing transformative digital solutions that shape a sustainable and prosperous tomorrow.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612653287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom